Fred Saad
Impact in
- Pulmonary and Respiratory Medicine top 0.01%
- Prostate Cancer Treatment and Research
- Prostate Cancer Diagnosis and Treatment
- Oncology top 0.05%
- Bone health and treatments
- PARP inhibition in cancer therapy
Papers in
-
- Prostate Cancer Treatment and Research 592
- Prostate Cancer Diagnosis and Treatment 245
- Renal cell carcinoma treatment 67
- Oncology 357
- Bone health and treatments 157
- Cancer Treatment and Pharmacology 65
- Co-authors
- Karim Fizazi (165 shared papers)Neal D. Shore (136 shared papers)Johann S. de Bono (73 shared papers)Cora N. Sternberg (83 shared papers)Kim N. (55 shared papers)Allan Lipton (31 shared papers)Paul N. Mainwaring (30 shared papers)Pierre I. Karakiewicz (251 shared papers)
- Journals
- Journal of Clinical Oncology (223 papers)The Journal of Urology (72 papers)Annals of Oncology (57 papers)Urologic Oncology Seminars and Original Investigations (45 papers)European Urology (43 papers)
- Partner nations
- CanadaUnited StatesGermany
In The Last Decade
Fred Saad
1.2k papers receiving 37.8k citations
Fred Saad's Hit Papers
Peers
Comparison fields: 5 of 157
- Pulmonary and Respiratory Medicine 21.3k
- Oncology 12.5k
- Cancer Research 5.0k
- Radiology, Nuclear Medicine and Imaging 5.4k
- Orthopedics and Sports Medicine 1.4k
Countries citing papers authored by Fred Saad
This map shows the geographic impact of Fred Saad's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fred Saad with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fred Saad more than expected).
Fields of papers citing papers by Fred Saad
This network shows the impact of papers produced by Fred Saad. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fred Saad. The network helps show where Fred Saad may publish in the future.
Co-authors
The 25 scholars most cited alongside Fred Saad, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 1.2k papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy Hit paper breakdown → | 2012 | 3428 |
| 2 | Olaparib for Metastatic Castration-Resistant Prostate Cancer Hit paper breakdown → | 2020 | 1473 |
| 3 | A Randomized, Placebo-Controlled Trial of Zoledronic Acid in Patients With Hormone-Refractory Metastatic Prostate Carcinoma Hit paper breakdown → | 2002 | 1301 |
| 4 | Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study Hit paper breakdown → | 2012 | 1069 |
| 5 | Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer Hit paper breakdown → | 2018 | 910 |
| 6 | Denosumab in Men Receiving Androgen-Deprivation Therapy for Prostate Cancer Hit paper breakdown → | 2009 | 855 |
| 7 | Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer Hit paper breakdown → | 2018 | 705 |
| 8 | Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases Hit paper breakdown → | 2011 | 607 |
| 9 | Pathologic fractures correlate with reduced survival in patients with malignant bone disease Hit paper breakdown → | 2007 | 523 |
| 10 | Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer Hit paper breakdown → | 2020 | 496 |
| 11 | Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials Hit paper breakdown → | 2012 | 446 |
| 12 | 2005 | 440 | |
| 13 | 2010 | 419 | |
| 14 | 2005 | 392 | |
| 15 | 2007 | 358 | |
| 16 | 2005 | 301 | |
| 17 | Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial Hit paper breakdown → | 2018 | 291 |
| 18 | Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer Hit paper breakdown → | 2020 | 275 |
| 19 | Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer Hit paper breakdown → | 2020 | 274 |
| 20 | 2001 | 264 |
About Fred Saad
Fred Saad is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Radiology, Nuclear Medicine and Imaging, Surgery and Cancer Research, having authored 1.2k papers that have together received 38.6k indexed citations. Recurring topics across this work include Prostate Cancer Treatment and Research (592 papers), Prostate Cancer Diagnosis and Treatment (245 papers), Radiopharmaceutical Chemistry and Applications (222 papers), Bone health and treatments (157 papers), Bladder and Urothelial Cancer Treatments (128 papers), Cancer, Lipids, and Metabolism (77 papers), Renal cell carcinoma treatment (67 papers) and Cancer Treatment and Pharmacology (65 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (21.3k citations), Oncology (12.5k citations), Cancer Research (5.0k citations), Radiology, Nuclear Medicine and Imaging (5.4k citations) and Orthopedics and Sports Medicine (1.4k citations). Fred Saad has collaborated with scholars based in Canada, United States and Germany. Frequent co-authors include Karim Fizazi, Neal D. Shore, Johann S. de Bono, Cora N. Sternberg, Kim N., Allan Lipton, Paul N. Mainwaring, Pierre I. Karakiewicz, Howard I. Scher and Kurt Miller. Their work appears in journals such as Journal of Clinical Oncology, The Journal of Urology, Annals of Oncology, Urologic Oncology Seminars and Original Investigations and European Urology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.